Home
ZOMETA MOA

ZOMETA MOA

For non-US healthcare professionals: Get information about ZOMETA and its product characteristics.

MOA in Advanced Solid Tumours and
Multiple Myeloma

This is an international site for Zometa^® (zoledronic acid) and is intended for Health Care Professionals outside the U.S. The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country.

Zometa Information for US residents Zometa Information for Patients Outside the US

Welcome to the ZOMETA Product Website

ZOMETA is approved for use in
95 countries
around the world.

ZOMETA Country-Level Websites

Below is a list of the countries that host a ZOMETA website based on local label and in local language. They are intended for Healthcare Professional (HCPs) only. Click on any of the links to be redirected to that country-level website.

ZOMETA International Website

This website is intended for Healthcare Professionals (HCPs) outside the U.S. The information on this website is not country specific and may contain information that is outside the approved indication in the country in which you are located. Please contact your local representative for local prescribing information via www.novartisoncology.com/contactus .

IMPORTANT: The information on this website is based on the European Summary of Product Characteristics (EUSmPC)

Text size:

ZOMETA fights devastating skeletal destruction in advanced solid tumours and multiple myeloma¹

As demonstrated in vitro, ZOMETA acts inside and outside the bone to break the vicious cycle of bone destruction^1-3

In addition to being a potent inhibitor of bone resorption, ZOMETA also possesses anticancer properties that could contribute to its overall efficacy in the treatment of metastatic bone disease, as shown in preclinical studies¹
- In vivo, ZOMETA alters the bone marrow microenvironment to make it less conducive to tumour cell growth, as well as inhibiting angiogenic activity
- In vitro, ZOMETA inhibits osteoblast proliferation, exerts direct cytostatic and pro-apoptotic activity on tumour cells, produces synergistic effects with other anticancer drugs, and inhibits tumour cell adhesion and invasion
ZOMETA uniquely inhibits the mevalonate pathway, an important mediator of tumour-cell and osteoclast function⁴

References: 1. ZOMETA Summary of Product Characteristics. Novartis Pharma AG. 2. Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;350:1655-1664. 3. Green JR. Bisphosphonates: preclinical review. Oncologist. 2004;9(suppl 4):3-13. 4. Neville-Webbe HL, Coleman RE. Bisphosphonates and RANK ligand inhibitors for the treatment and prevention of metastatic bone disease. Eur J Cancer. 2010;46:1211-1222.

MOA in Advanced Solid Tumours andMultiple Myeloma